西格列汀对2型糖尿病患者血清ET-1和NO的影响

目的:观察西格列汀对2型糖尿病患者血清内皮素-1(ET-1)、一氧化氮(NO)含量的影响。方法:60例2型糖尿病患者随机分实验组和对照组各30例。实验组给予磷酸西格列汀和格华止口服,共12周;对照组给予拜糖平和格华止口服,共12周。记录比较治疗前后血清ET-1、NO、空腹血糖(FPG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbA c)及血脂含量。结果:两组患者血清ET-1、FPG、2hPG、HbA1c均较治疗前明显下降(P<0.05),NO均较治疗前明显升高(P<0.05),血脂变化不明显;实验组血清ET-1较对照组明显下降(P<0.05),实验组血清NO较对照组明显升高(P<0.05)。结论:西格列汀能有效降低2型糖尿病患者血清ET-1和升高NO含量的作用。

Effects of Sitagliptin on serum endothelin-1 and nitric oxide for patients with type 2 diabetes

ObjectiveTo observe effects of Sitagliptin on endothelin-1 （ET-1） and nitric oxide （NO） for patients with type 2diabetes. Methods：Sixty newly-diagnosed type 2 diabetic patients were randomly divided into treatment group and control group. Thecases in treatment group orally took Sitagliptin and glucophage for 12 weeks, while those in control group orally took acarbose and glu鄄cophage for 12 weeks. The contents of serum ET-1 and NO, fasting plasma glucose （FPG） and 2h postprandial plasma glucose（2hPG）, glycosylated hemoglobin （HbA1c ）, and serum lipids were recorded and compared. Results： Compared with those before thetreatment, the contents of serum ET-1, FPG, 2hPG and HbA1c of the two groups decreased obviously after the treatment （P〈0. 05）,NO contents significantly increased （P〈0. 05）, but blood lipid did not show any changes. The serum ET-1 content of treatment groupdecreased more significantly than that of control group （P〈0. 05）, and the serum NO content of treatment group increased more signifi-cantly than that of control group （P〈0. 05）. Conclusions： Sitagliptin can effectively reduce the serum ET-1 but increase NO for thepatients with type 2 diabetes.